Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 01, 2005. The report details a specific corporate action regarding the repurchase of the company's own shares, authorized by shareholders at the Annual General Meeting on May 25, 2005.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 1,400,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,447.26 pence per share.
- Transaction Date: December 01, 2005.
Material Changes
Following the repurchase, the Company's share capital structure changed as follows:
- Treasury Shares: The total number of shares held in Treasury increased to 127,658,000.
- Shares in Issue: The total number of shares in issue (excluding Treasury shares) stands at 5,826,341,063.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase or subscribe for securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the 1,400,000 share repurchase based on the disclosed price of 1,447.26 pence.
- Confirm the updated total share count (5,826,341,063) against subsequent filings to ensure accuracy.
- Review the Annual General Meeting minutes from May 25, 2005, to understand the full scope of the share buyback authorization.
- Note that this filing does not contain operational or financial performance data for the period.